APOB and hepatocellular carcinoma: TM6SF2 has been widely studied in connection to rs58542926:T, another missense variant that is itself associated with HCC and also liver cirrhosis(4, 6, 15, 34) but interestingly protects from CVDs.(35) Previous work indicates that loss of TM6SF2 function increases hepatocyte fat content by reducing APOB secretion.(36) This is consistent with a study by Pelusi et al.(37) showing that individuals with rare pathogenic variants in APOB are at increased risk of HCC.